A Randomized, Placebo Controlled Study to Determine the Efficacy and Speed of a Nasal Spray in Allergen Induced Seasonal Allergic Rhinitis
Information source: Bayer
Information obtained from ClinicalTrials.gov on August 08, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Seasonal Allergic Rhinitis
Intervention: Azelastine Nasal Spray (BAYR9258) (Drug); Placebo (Drug); Placebo (Drug); Placebo (Drug)
Phase: Phase 4
Status: Recruiting
Sponsored by: Bayer Official(s) and/or principal investigator(s):
Bayer Study Manager, Study Director, Affiliation: Bayer
Overall contact:
Bayer Clinical Trials Contact, Email: clinical-trials-contact@bayerhealthcare.com
Summary
Finding out how fast azelastine nasal spray works in subjects with hay fever.
Clinical Details
Official title: A Four-Way Double-Blind, Randomized, Placebo Controlled Study to Determine the Efficacy and Speed of Azelastine Nasal Spray and Antihistaminic Agents in Adult Subjects With Allergen Induced Seasonal Allergic Rhinitis
Study design: Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Single Group Assignment, Efficacy Study
Primary outcome: Onset of action measured by change from baseline in total nasal symptom score.
Secondary outcome: Change from baseline for individual symptoms of allergic seasonal rhinitis; overall assessment of efficacy
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- History of seasonal allergic rhinitis to ragweed pollen for last 2 consecutive
seasons
- Positive response to skin prick test to ragweed allergen at screening;
- Be willing to participate in the trial.
Exclusion Criteria:
- History of hypersensitivity to azelastine
- Females who are pregnant or lactating
- Relative chronic sinusitis or nasal structural abnormalities causing greater than 50%
obstruction
- Asthma that requires other than occasional use of inhaled short-acting beta-2
antagonist
- Known non-responsiveness to antihistamines
- Alcoholism or drug abuse within 2 yrs. of screening
- Current or regular use within 6 months of any type of tobacco product
- Evidence of any clinically significant hematological, renal, endocrine, pulmonary,
gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic or malignancies
within the last 5 years
- History of a positive test to HIV, TB, hepatitis B or C.
Locations and Contacts
Bayer Clinical Trials Contact, Email: clinical-trials-contact@bayerhealthcare.com
Bayer Clinical Research Center, Kingston, Canada; Recruiting
Additional Information
Click here and search for drug information provided by the FDA Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product
Starting date: October 2007
Ending date: December 2007
Last updated: November 20, 2007
|
